( )
Click to enlarge.
Gene Synthesis
Aldevron is pleased to offer our clients full-featured gene synthesis capability to compliment our best-in-class plasmid, protein, and antibody manufacturing platforms.
Our client relations specialists can handle your request seamlessly from sequence or accession number, straight through to deliverable material manufactured to your specifications. Aldevrons’ state-of-the-art quality systems ensure your material will meet your exacting standards.
Features and Benefits:
Frequently asked Questions:
What is gene optimization?
Gene optimization adjusts the codon usage for the “preference” of the intended expression system and accounts for dozens of factors that can compromise the stability of your mRNA, such as extreme GC content, ribosomal binding sites, consensus and cryptic splice sites, repeats and secondary structures. Increased numbers of stable mRNAs can lead to higher yields of protein.
Can you synthesize sequences with high GC content or repeats?
Yes. Our proprietary technologies enable us to synthesize sequences with difficult stretches. Our bioinformatics platform can optimize your gene for synthesis. We carefully review every sequence, and provide a customized quote including the turnaround time and price.
Is there any extra charge in addition to the per bp price?
We provide a customized quote for every sequence. For typical gene sequences (i.e. less than 2kb, free of difficult stretches like highly repetitive, AT-rich, or GC-rich fragments) that do not require subcloning into the customer's own vector, there will be no extra charge to the per bp price. For difficult sequences, or projects with subcloning requirements, additional charges will be itemized on the customized quote. Your price will be exactly as quoted.
My vector is a commonly used expression vector. Do you have it in stock?
Vectors other than pUC57 must be supplied by our clients unless special arrangements have been made.
How will I be assured that I'm getting the correct sequence?
We have controls in place throughout a project to ensure the accurate synthesis of your sequence.
- The exact sequence to be synthesized is included in the custom quote for your project, facilitating your review and confirmation prior to project initiation.
- Sequence verification during the assembly process helps confirm that any subassemblies contain the intended sequence.
- The final construct is clonally isolated and confirmed to match the quoted sequence.
- The electronic data package delivered in parallel with your construct contains the original sequencing data files from the construct verification for your independent review
Also included in this package:
- A certificate of authentication with a restriction digest image of the sample.
- An alignment of the sequencing data with the complete insert sequence.
- The predicted complete vector sequence.
What lengths of synthetic genes can you synthesize?
We can synthesize gene sequences from 100 bp to 50 kb, using short DNA oligos as building blocks.
How do you synthesize genes?
Single-stranded oligonucleotides are designed, synthesized, and assembled using different protocols depending on the sequence characteristics. The assembled full-length gene is subsequently cloned into the vector pUC57, and the insert is verified by DNA sequencing and restriction digestion.
What restriction sites do you use to clone the synthetic genes into pUC57?
We clone the synthetic genes into the EcoRV site in pUC57 . A customer may also specify the restriction site for cloning.
Can you clone the synthetic gene directly into my vector and save the step of cloning into pUC57?
Yes. We are happy to clone your sequence into your vector. Cloning into pUC57 is part of our standard procedure, helping ensure accurate construction of your sequence. As part of our quality control, all constructs are cloned and sequence verified in pUC57 prior to custom cloning into your vector.
Full Service
Sequence design and optimization, synthesis, cloning (standard pUC57), sequence verification, restriction digestion, and plasmid preparation to most any specification required from research through clinical applications.
Rapid Turnaround
Approximately 2 - 3 weeks for <2 kb synthetic genes.
Intellectural Property Security
Aldevron does not claim rights or ownership of any intellectual property related to the DNA/amino acid sequences provided by our customers or the resulting synthetic genes. All intellectual properties are protected by our strict company-wide IP policy. No data or material will be released to a third party.
Industry Leading Technology
Proprietary technologies enable synthesis of sequences with difficult stretches like highly repetitive, AT-rich, and GC-rich DNA. Our bioinformatics platform optimizes your desired sequences for better expression and your specific needs.
Consultation & Support
Our scientists tailor your order to your exact specifications, and support you throughout the entire project.
Standard Deliverables:
- 2-5 ug (depending on vector) of lyophilized plasmid containing the desired synthetic construct
- Certificate of Analysis (COA) including restriction digest
- Sequence trace data with alignment
- Sequence of synthetic gene alone and in vector
What antibiotic resistance gene is found in pUC57?
Ampicillin
What is your recommended DNA resuspension protocol?
The sample tube contains 2-5 ug (depending on vector) of lyophilized plasmid DNA. To resuspend it, we recommend:
- Spin the tube briefly to ensure that the contents are on the bottom of the tube.
- Resuspend the sample in a volume appropriate for your needs (such as 20-50 uL for ~0.25 to ~0.1 ug/uL) of either sterile, high purity water or TE (resuspension solution depends on your downstream applications; TE may interfere with enzyme activity)
- Vortex briefly, let sit 2-10 minutes on ice, then vortex again.
Do you have any mechanism for addressing potential biosecurity concerns that may arise with the genes that you synthesize?
Aldevron is fully aware that Gene Synthesis technology potentially enables the de novo reconstruction of dangerous pathogens, and of the need for an in-house mechanism to safeguard against intentional or unintentional abuse of the genes that we synthesize. We are monitoring the progress of the Screening Framework Guidance for Synthetic Double-Stranded DNA Providers, drafted by U.S. Department of Health and Human Services (HHS).